Therabest USA

Therabest is a biotechnology company specializing in the development of next-generation off-the-shelf cell therapies using induced pluripotent stem cells (iPSCs). The company's primary focus is its EiNK platform, which produces high-purity, mass-producible Natural Killer (NK) cells designed to treat various cancers. Its lead program, TB-101, is an iPSC-derived NK cell therapy targeting solid tumors and hematologic malignancies. Therabest USA serves as the company's clinical and strategic hub in the United States to facilitate global development and regulatory engagement. The company's technology aims to provide a cost-effective and scalable alternative to traditional autologous cell therapies.